Search

Women who use second-generation oral contraceptives have twice the risk of having a heart attack as women who do not use oral contraceptives, according to a study of 1,173 women. Women can lower this risk by using third-generation oral contraceptives.

Breast arterial calcification (BAC) has been associated with diabetes and hypertension. This prompted the authors to study the relation between BAC and cardiovascular mortality in a cohort of 12,239 women aged 50–68 years who participated in a population-based breast cancer screening project (DOM Project) in Utrecht, the Netherlands, during the period 1975–1977. Mortality data from 16–19 years of follow-up were available. The occurrence of outcome events was compared in terms of hazard ratios. Cardiovascular risk factors, including age, diabetes mellitus, hypertension, parity, Quetelet index, and smoking, were studied to identify possible confounders. Arterial calcification was seen in 9% of the women. The hazard ratio for overall mortality was 1.29 (95% confidence interval 1.06–1.58) in women with BAC detected on screening mammograms in comparison with women without BAC after correction for the above-mentioned factors. An excess of all-cause mortality was found in diabetic women with BAC (hazard ratio = 1.74, 95% confidence interval 1.19–2.56), which was also present in subgroups of coronary mortality. These results indicate that BAC is associated with an increased risk of subsequent cardiovascular death in women over age 50 years and in diabetic women in particular. Am J Epidemiol 1998; 147: 333–41. [ABSTRACT FROM AUTHOR]

During the 2009 influenza pandemic, children aged 6 months up to and including 4 years, without chronic illness, were vaccinated with two doses of Pandemrix(®) through mass vaccination in the Netherlands. During the vaccination campaign a warning was issued about fever after the second dose of Pandemrix(®). Therefore, we investigated the tolerability of both doses Pandemrix(®) in these children. Among parents of children eligible for vaccination, 1500 questionnaires were distributed during both, the first and second mass vaccination session. We asked for the occurrence, time interval, and duration of local reactions and systemic adverse events (AEs). The responses were 36.7% and 29.5% after each dose, respectively. Local reactions were reported in 40.4% and 39.3%, most frequently, pain at the injection site. After the first and second dose, 29.6% and 30.7% of all children experienced fever (mean temperature 38.8{degree sign}C). Other systemic AEs were reported in 41.6% and 42.9% of the children. No differences were seen between the first and second dose for all reported AEs except for pallor. One child was hospitalized after the first dose, but a causal relation to the vaccination was considered improbable. In conclusion, fever was frequently reported in children 6 months up to and including 4 years of age after the first and second dose of Pandemrix(®). However, for almost all AEs, including fever, no dose effect was observed. Reported AEs were mostly mild and all were transient.

Aim: To study the safety profile of the bivalent human papillomavirus (HPV) vaccine following administration of a first dose to 192,119 13-16-year-old girls in the context of a catch-up campaign., Design: Descriptive., Methods: The safety of the HPV campaign underwent surveillance in three ways: via a spontaneous reporting system, whereby anyone could report a possible undesirable effect; following completion and validation a diagnosis was made and the causal relationship with the vaccination assessed. Secondly, general healthcare service (GGD) physicians reported effects that occurred during the vaccination sessions. Thirdly, we conducted a questionnaire survey of frequent possible side effects, in which we asked about effects that occurred up to 1 week after the vaccine., Results: 446 reports were received via the spontaneous reporting system (degree of reporting: 23.2:10,000). 16% of reports were mainly local effects; 84% were systemic effects, including 8 severe effects. 157 girls consulted their general practitioner or went to a hospital (degree of reporting: 8:10,000). 59% of the reports were of a side effect; in 41% a concurrent event was coincidental. There were 638 reports during the vaccination sessions (degree of reporting 45:10,000). The largest number were vasovegetative effects, including fainting or near-fainting (n = 569; degree of reporting: 40:10,000). The degree of reporting of tightness of the chest or skin effects was 2:10,000. The assistance of a general practitioner or ambulance was summoned for 10 girls (degree of reporting: 0.7:10,000). The questionnaire study (response 68.7%; n = 3646) showed that 92.1% of the girls had local effects. In 1.6% these symptoms were severe. Systemic effects occurred in 91.7%; 0.7% had fever (>or= 39.5 degrees C). 1.5% of girls called for medical assistance., Conclusion: During intensive surveillance of safety of the HPV campaign, no unexpected or serious side effects with a causal relationship with the vaccination occurred following administration of 192,119 doses. In accordance with data from foreign studies, side effects may be common, but are in general mild and short-lived.